These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 25376612)

  • 1. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.
    Larsen AR; Bai RY; Chung JH; Borodovsky A; Rudin CM; Riggins GJ; Bunz F
    Mol Cancer Ther; 2015 Jan; 14(1):3-13. PubMed ID: 25376612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
    Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ
    Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
    Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
    Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel hedgehog inhibitor for the treatment of hematological malignancies.
    Lin P; He Y; Chen G; Ma H; Zheng J; Zhang Z; Cao B; Zhang H; Zhang X; Mao X
    Anticancer Drugs; 2018 Nov; 29(10):995-1003. PubMed ID: 30106753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
    Li QR; Zhao H; Zhang XS; Lang H; Yu K
    Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
    Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
    Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma.
    Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ
    Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
    Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
    Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Berberine, a natural compound, suppresses Hedgehog signaling pathway activity and cancer growth.
    Wang J; Peng Y; Liu Y; Yang J; Ding N; Tan W
    BMC Cancer; 2015 Aug; 15():595. PubMed ID: 26296751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened.
    Liu YB; He LM; Sun M; Luo WJ; Lin ZC; Qiu ZP; Zhang YL; Hu A; Luo J; Qiu WW; Song BL
    Cell Chem Biol; 2024 Jul; 31(7):1264-1276.e7. PubMed ID: 38442710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
    Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with Hedgehog pathway inhibitors.
    Low JA; de Sauvage FJ
    J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
    Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
    Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vismodegib.
    Meiss F; Andrlová H; Zeiser R
    Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.
    Rohner A; Spilker ME; Lam JL; Pascual B; Bartkowski D; Li QJ; Yang AH; Stevens G; Xu M; Wells PA; Planken S; Nair S; Sun S
    Mol Cancer Ther; 2012 Jan; 11(1):57-65. PubMed ID: 22084163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RETRACTED: CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance.
    Yoon C; Park DJ; Schmidt B; Thomas NJ; Lee HJ; Kim TS; Janjigian YY; Cohen DJ; Yoon SS
    Clin Cancer Res; 2014 Aug; 20(15):3974-88. PubMed ID: 24947926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
    Gordon RE; Zhang L; Peri S; Kuo YM; Du F; Egleston BL; Ng JMY; Andrews AJ; Astsaturov I; Curran T; Yang ZJ
    Clin Cancer Res; 2018 Mar; 24(6):1375-1388. PubMed ID: 29437795
    [No Abstract]   [Full Text] [Related]  

  • 19. Gli as a novel therapeutic target in malignant pleural mesothelioma.
    Li H; Lui N; Cheng T; Tseng HH; Yue D; Giroux-Leprieur E; Do HT; Sheng Q; Jin JQ; Luh TW; Jablons DM; He B
    PLoS One; 2013; 8(3):e57346. PubMed ID: 23483902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers.
    Long J; Li B; Rodriguez-Blanco J; Pastori C; Volmar CH; Wahlestedt C; Capobianco A; Bai F; Pei XH; Ayad NG; Robbins DJ
    J Biol Chem; 2014 Dec; 289(51):35494-502. PubMed ID: 25355313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.